The Patent Finder

Terms ending in 2040

Chemocentryx, Inc.

Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 10,792,360Compositions and Methods for Treating Inflammatory Bowel Disease Using CCR9 Inhibitor and Anti-Tnf-Alpha Blocking Antibodies
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,608,336PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,986,466Methods of Treating Solid Tumors with CCR2 Antagonists
In force
 · High confidence
The Regents of the University of CaliforniaIn forceHigh confidence
US 11,266,643Triaryl Compounds for Treatment of PD-L1 Diseases
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 12,533,354Triaryl Compounds for Treatment of PD-L1 Diseases
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,446,289Combination Therapy Using C-C Chemokine Receptor 4 (CCR4) Antagonists and One or More Immune Checkpoint Inhibitors
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,485,708Compounds for Treatment of PD-L1 Diseases
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 11,872,217Indanes as PD-L1 Inhibitors
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 12,371,433Heteroaryl-Biphenyl Amines for the Treatment of PD-L1 Diseases
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
US 12,497,383Heteroaryl-Biphenyl Amides for the Treatment of PD-L1 Diseases
In force
 · High confidence
Chemocentryx, Inc.In forceHigh confidence
2 more term ends in 2040 · Pro
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
Upgrade to Pro
11 of these are in force and held by Chemocentryx, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited